Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
1.820
+0.070 (4.00%)
At close: May 20, 2025, 4:00 PM
1.850
+0.030 (1.63%)
After-hours: May 20, 2025, 4:50 PM EDT
Aditxt Revenue
Aditxt had revenue of $1.02K in the quarter ending March 31, 2025, a decrease of -98.72%. This brings the company's revenue in the last twelve months to $55.32K, down -89.08% year-over-year. In the year 2024, Aditxt had annual revenue of $133.99K, down -79.23%.
Revenue (ttm)
$55.32K
Revenue Growth
-89.08%
P/S Ratio
5.98
Revenue / Employee
$2,128
Employees
26
Market Cap
2.11M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ADTX News
- 1 day ago - Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics - Business Wire
- 18 days ago - Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Business Wire
- 4 weeks ago - Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™ - Business Wire
- 4 weeks ago - Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 - Business Wire
- 5 weeks ago - Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Business Wire
- 5 weeks ago - Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements - Business Wire
- 5 weeks ago - Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements - Business Wire
- 6 weeks ago - Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025 - Business Wire